DelveInsight’s ‘CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) – Market Insights and Market Forecast-2030’ report delivers an in-depth understanding of the CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) and market trends in the 6MM, i.e., United States and EU5 (Germany, Spain, Italy, France and United Kingdom).
Some of the key facts of the report
1. Non-Hodgkin’s Lymphoma is one of the types of blood cancer that affects lymphocytes.
2. Diffuse large B-cell Lymphoma (DLBCL) is the most common type of NHL that accounts for about 22% of newly diagnosed cases of B-cell NHL in the United States.
3. B-cell lymphomas consist of around 85% of all NHL cases that are diagnosed in the United States.
Key benefits of the report
1. CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma market report covers a descriptive overview and comprehensive insight and CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma market in the 6 MM (the United States, EU5 (Germany, Spain, France, Italy, UK).
2. CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma market report provides insights on the current and emerging therapies.
3. CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma market report provides a global historical and forecasted market covering drug outreach in 6 MM.
4. CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma market.
“The Market Size of CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma in the 6MM is estimated to be USD 2796.2 Million in 2030.”
Scope of the Report
- The report covers the descriptive overview of CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL), explaining causes, signs and symptoms, pathophysiology and currently available therapies for NHL and
- Comprehensive insight has been provided into the CAR T-Cell Therapy for Non-Hodgkin’s lymphoma treatment in the US and EU5
- Additionally, an all-inclusive account of both the current and emerging CAR T-Cell Therapies for Non-Hodgkin’s lymphoma (NHL) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of CAR T-Cell Therapy for Non-Hodgkin’s lymphoma market; historical and forecasted is included in the report, covering drug outreach in the US and EU5
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global CAR T-Cell Therapy for Non-Hodgkin’s lymphoma market
Report Highlights:
- In the coming years, CAR T-Cell Therapy for Non-Hodgkin’s lymphoma market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the therapy manufacturers to penetrate more into the market
- The companies and academics are working to assess challenges and seek opportunities that could influence CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
- Major players are involved in developing CAR T-Cell Therapies for Non-Hodgkin’s lymphoma (NHL). Launch of emerging therapies, will significantly impact the Non-Hodgkin’s lymphoma market
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL)
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Table of contents
1 Key Insights
2 Executive Summary
3 CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Market Overview at a Glance
4 CAR T-Cell Therapy Background and Overview
5 CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Treatment Algorithm, Current Treatment, and Medical Practices
6 Unmet Needs
7 Key Endpoints of Non-Hodgkin’s Lymphoma Treatment
8 Marketed CAR T-Cell Therapies for Non-Hodgkin’s Lymphoma
8.1 List of Marketed Products in the 6MM
8.2 KYMRIAH: NOVARTIS
8.3 YESCARTA: Kite Pharma (Gilead Sciences)
9 Emerging CAR T-Cell Therapies for Non-Hodgkin’s Lymphoma
9.1.1 KTE-X19 : Gilead Sciences
9.1.2 JCAR017: Celgene Corporation (a BMS company)
10 CAR T-Cell Therapy for NHL: Six Major Market Analysis
11 Attribute analysis
12 6MM: Market Outlook
12.2 EU-5 Market Size
12.2.1 Germany
12.2.2 France
12.2.3 Italy
12.2.4 Spain
12.2.5 United Kingdom
13 CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Clinical Trials in 6MM
14 KOL Views – CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma
15 Market Drivers
16 Market Barriers
17 Appendix
18 DelveInsight Capabilities
19 Disclaimer
20 About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/